Early clinical development of ARQ 197, a selective, Non-ATP-competitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancers

Alex A. Adjei, Brian Schwartz, Edward Garmey

Research output: Contribution to journal › Article › peer-review

58 Scopus citations

Fingerprint

Dive into the research topics of 'Early clinical development of ARQ 197, a selective, Non-ATP-competitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancers'. Together they form a unique fingerprint.

Medicine & Life Sciences